BRÈVE

sur Videra Surgical

Study Indicates Significant Radiation Reduction for Breast Cancer Patients

A recent study accepted by the American Society of Radiation Oncology (ASTRO) highlights a significant reduction in radiation Planning Target Volume for patients who underwent Breast Conserving Surgery (lumpectomy) with the VeraForm® marker and Accelerated Partial Breast Irradiation (APBI) alongside Deep Inspiration Breath Hold (DIBH). Developed by Videra Surgical, VeraForm is a 3D, radiopaque marker. The findings demonstrated an average reduction of over 80% in radiation volume.

Conducted by the Inova Health System in Virginia, the study involved 76 lumpectomy patients who received 5-fraction external beam APBI with DIBH. Over a two-year follow-up, the results showed substantial reduction in PTV without compromising local control. Dr. Ashish Chawla from Inova Schar Cancer Institute emphasized that advanced target delineation with VeraForm reduces overall radiation exposure.

Dr. Shawna Willey noted that minimizing radiation benefits patients by reducing potential side effects. The study underscores the precision of VeraForm in tumor bed delineation. Joe Guido, CEO of Videra Surgical, expressed pride in the study's acceptance by ASTRO and its publication in the International Journal of Radiation Oncology.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Videra Surgical